This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Liver cancer	Transcription factor CP2 (TFCP2; LSF)	<i>In vitro</i> and mouse studies identified a small molecule inhibitor of the transcription factor LSF that could help treat hepatocellular carcinoma (HCC). In assays, factor quinoline inhibitor 1 (FQI1) inhibited the DNA-binding activity of LSF and transcriptional stimulation of LSF-dependent reporter constructs. In an aggressive HCC cell line that overexpressed LSF, FQI1 decreased viability and proliferation compared with vehicle control. In mice with human HCC xenografts, FQI1 lowered tumor growth and vasculature compared with vehicle control and did not show toxicity. Next steps include additional pharmacokinetic testing.	Patent application filed; available for licensing	Grant, T.J. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online March 5, 2012; doi:10.1073/pnas.1121601109 Contact: Ulla Hansen, Boston University, Boston, Mass. e-mail: uhansen@bu.edu
<i>SciBX</i> 5(12); doi:10.1038/scibx.2012.305 Published online March 22, 2012				